0001104659-21-052205.txt : 20210420 0001104659-21-052205.hdr.sgml : 20210420 20210420073848 ACCESSION NUMBER: 0001104659-21-052205 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210420 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210420 DATE AS OF CHANGE: 20210420 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 21836305 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 8-K 1 tm2113390d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

April 20, 2021

Date of Report (Date of earliest event reported)

ABBOTT LABORATORIES

(Exact name of registrant as specified in charter)

Illinois		1-2189		36-0698440
(State or other Jurisdiction		(Commission File Number)		(IRS Employer
of Incorporation)				Identification No.)

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (224) 667-6100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common Shares, Without Par Value	ABT	New York Stock Exchange Chicago Stock Exchange, Inc.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02

Results of Operations and Financial Condition

On April 20, 2021, Abbott Laboratories announced its results of operations for the first quarter 2021.

Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings from continuing operations excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, restructuring actions, cost reduction initiatives, certain litigation, the acquisition of an R&D asset, the impairment of certain assets, tax benefits associated with specified items, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.

Item 9.01

Financial Statements and Exhibits

	Exhibit No.	Exhibit

	99.1	Press Release dated April 20, 2021 (furnished pursuant to Item 2.02).

	104	Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ABBOTT LABORATORIES

Date: April 20, 2021	By:	/s/ Robert E. Funck, Jr.
		Robert E. Funck, Jr.
		Executive Vice President, Finance and Chief Financial Officer

EX-99.1 2 tm2113390d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

News Release

Abbott Reports First-Quarter 2021 Results

	-	Sales growth of 35.3 percent; organic sales growth of 32.9 percent
	-	GAAP diluted EPS growth from continuing operations of 233.3 percent; adjusted diluted EPS growth of 103.1 percent
	-	All four major businesses achieved strong sales growth in the quarter
	-	Projected full-year EPS remains unchanged; reflects growth of more than 35 percent

ABBOTT PARK, Ill., April 20, 2021 — Abbott today announced financial results for the first quarter ended March 31, 2021.

·

First-quarter sales of $10.5 billion increased 35.3 percent on a reported basis and 32.9 percent on an organic basis, which excludes the impact of foreign exchange.

·

First-quarter GAAP diluted EPS was $1.00 and adjusted diluted EPS, which excludes specified items, was $1.32, reflecting 103.1 percent growth versus the prior year.¹

·

Abbott projects full-year 2021 diluted EPS from continuing operations on a GAAP basis of at least $3.74. Projected full-year adjusted diluted EPS from continuing operations of at least $5.00 remains unchanged and reflects growth of more than 35 percent versus the prior year.²

·

Global COVID-19 testing-related sales were $2.2 billion in the first quarter, led by combined sales of $1.8 billion from Abbott's BinaxNOW^™, Panbio^™ and ID NOW^™ rapid testing platforms.

·

First-quarter sales increased 7.6 percent on a reported basis and 5.7 percent on an organic basis, excluding COVID-19 testing-related sales.

·

In January, the U.S. Centers for Medicare & Medicaid Services expanded reimbursement coverage eligibility for Abbott's revolutionary MitraClip^™ device, which significantly increases the number of people who can benefit from this market-leading, minimally invasive heart device.

·

In March, Abbott announced the U.S. launch of NeuroSphere^™ Virtual Clinic, a first-of-its-kind technology that allows patients to communicate with physicians, ensure proper settings and functionality, and receive new treatment settings remotely as needed.

·

In April, Abbott announced U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) of its BinaxNOW COVID-19 Ag Self Test for individuals with or without symptoms and without the need of a prescription.

"We're off to a very strong start to the year, with all four of our major businesses achieving strong growth," said Robert B. Ford, president and chief executive officer, Abbott. "We're particularly pleased with the growing momentum of several recently launched products and continue to forecast more than 35 percent EPS growth for the year."

—more—

First-Quarter Business Overview

Note: Management believes that measuring sales growth rates on an organic basis is an appropriate way for investors to best understand the underlying performance of the business. Organic sales growth excludes the impact of foreign exchange.

Following are sales by business segment and commentary for the first quarter 2021:

Total Company

($ in millions)

														% Change vs. 1Q20
		Sales 1Q21												Reported												Organic
		U.S.				Int'l				Total				U.S.				Int'l				Total				U.S.				Int'l				Total
Total *			3,838				6,618				10,456				34.4				35.9				35.3				34.4				32.0				32.9
Nutrition			836				1,200				2,036				3.0				9.8				6.9				3.0				9.0				6.4
Diagnostics			1,641				2,373				4,014				104.4				131.9				119.8				104.4				122.9				114.8
Established Pharmaceuticals			--				1,070				1,070				n/a				2.5				2.5				n/a				6.2				6.2
Medical Devices			1,351				1,969				3,320				9.6				15.6				13.1				9.6				8.2				8.8

* Total Q1 2021 Abbott sales from continuing operations include Other Sales of approximately $16 million.

n/a = Not Applicable.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

First-quarter 2021 worldwide sales of $10.5 billion increased 35.3 percent on a reported basis and 32.9 percent on an organic basis.

2

Nutrition

($ in millions)

																% Change vs. 1Q20
				Sales 1Q21												Reported												Organic
				U.S.				Int'l				Total				U.S.				Int'l				Total				U.S.				Int'l				Total
	Total				836				1,200				2,036				3.0				9.8				6.9				3.0				9.0				6.4
	Pediatric				508				558				1,066				(1.8	)			(2.3	)			(2.1	)			(1.8	)			(3.1	)			(2.5	)
	Adult				328				642				970				11.4				23.1				18.9				11.4				22.1				18.3

Worldwide Nutrition sales increased 6.9 percent on a reported basis and 6.4 percent on an organic basis in the first quarter. Strong performance of Ensure^®, Abbott's market-leading complete and balanced nutrition brand, and Glucerna^®, Abbott's market-leading diabetes nutrition brand, led to global Adult Nutrition sales growth of 18.9 percent on a reported basis and 18.3 percent on an organic basis. In Pediatric Nutrition, sales growth was negatively impacted by a difficult comparison versus the first quarter of 2020 when consumers increased purchases in advance of stay-at-home directives as a result of COVID-19.

Diagnostics

($ in millions)

														% Change vs. 1Q20
		Sales 1Q21												Reported												Organic
		U.S.				Int'l				Total				U.S.				Int'l				Total				U.S.				Int'l				Total
Total			1,641				2,373				4,014				104.4				131.9				119.8				104.4				122.9				114.8
Core Laboratory			271				911				1,182				1.9				26.1				19.6				1.9				21.3				16.1
Molecular			175				272				447				168.7				267.0				220.9				168.7				250.2				212.0
Point of Care			92				37				129				(11.4	)			7.8				(6.6	)			(11.4	)			3.8				(7.6	)
Rapid Diagnostics			1,103				1,153				2,256				199.7				500.6				302.8				199.7				477.7				295.0

Worldwide Diagnostics sales increased 119.8 percent on a reported basis in the first quarter and increased 114.8 percent on an organic basis. Strong growth in the quarter was driven by demand for Abbott's portfolio of COVID-19 diagnostics tests across its rapid and lab-based platforms. Global COVID-19 testing-related sales were $2.2 billion in the first quarter, led by combined sales of $1.8 billion from Abbott's BinaxNOW, Panbio and ID NOW rapid testing platforms.

Excluding COVID-19 testing-related sales, Core Laboratory Diagnostics sales increased 10.7 percent and Molecular Diagnostics sales increased 31.5 percent on an organic basis in the first quarter.³

3

Established Pharmaceuticals

($ in millions)

														% Change vs. 1Q20
		Sales 1Q21												Reported												Organic
		U.S.				Int'l				Total				U.S.				Int'l				Total				U.S.				Int'l				Total
Total			--				1,070				1,070				n/a				2.5				2.5				n/a				6.2				6.2
Key Emerging Markets			--				821				821				n/a				1.0				1.0				n/a				6.7				6.7
Other			--				249				249				n/a				7.8				7.8				n/a				4.2				4.2

Established Pharmaceuticals sales increased 2.5 percent on a reported basis in the first quarter and increased 6.2 percent on an organic basis.

Key Emerging Markets include India, Brazil, Russia and China along with several additional emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 1.0 percent on a reported basis in the quarter and increased 6.7 percent on an organic basis. Organic sales growth was led by strong growth across several geographies, including China, India and Brazil.

Other sales increased 7.8 percent on a reported basis in the quarter and increased 4.2 percent on an organic basis.

Medical Devices

($ in millions)

														% Change vs. 1Q20
		Sales 1Q21												Reported												Organic
		U.S.				Int'l				Total				U.S.				Int'l				Total				U.S.				Int'l				Total
Total			1,351				1,969				3,320				9.6				15.6				13.1				9.6				8.2				8.8
Rhythm Management			241				278				519				5.6				13.4				9.6				5.6				6.1				5.8
Electrophysiology			179				252				431				9.3				12.3				11.0				9.3				5.5				7.1
Heart Failure			145				49				194				(4.7	)			(4.3	)			(4.6	)			(4.7	)			(10.8	)			(6.2	)
Vascular			219				416				635				(4.7	)			5.4				1.7				(4.7	)			(0.4	)			(2.0	)
Structural Heart			169				208				377				24.3				14.3				18.6				24.3				6.7				14.2
Neuromodulation			145				39				184				6.1				(1.4	)			4.4				6.1				(8.3	)			2.8
Diabetes Care			253				727				980				35.7				28.3				30.2				35.7				19.5				23.6

Worldwide Medical Devices sales increased 13.1 percent on a reported basis in the first quarter and increased 8.8 percent on an organic basis. Strong growth in the quarter was driven by continued recovery from the COVID-19 pandemic. In Diabetes Care, sales of FreeStyle^® Libre and Libre Sense were $829 million in the quarter. FreeStyle Libre now has more than 3 million users worldwide.

4

Abbott’S EARNINGS-PER-SHARE guidance

Abbott projects 2021 diluted earnings per share from continuing operations under Generally Accepted Accounting Principles (GAAP) of at least $3.74. Abbott forecasts specified items for the full-year 2021 of $1.26 primarily related to intangible amortization, expenses associated with acquisitions, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be at least $5.00 for full-year 2021.

Abbott declares 389^th consecutive QUARTERLY DIVIDEND

On Feb. 19, 2021, the board of directors of Abbott declared the company’s quarterly dividend of $0.45 per share. Abbott's cash dividend is payable May 17, 2021 to shareholders of record at the close of business on April 15, 2021.

Abbott has increased its dividend payout for 49 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

Abbott will live webcast its first-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8:30 a.m. Central time today. An archived edition of the webcast will be available later that day.

5

— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2020, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Abbott Financial:

Scott Leinenweber, 224-668-0791

Michael Comilla, 224-668-1872

Laura Dauer, 224-667-2299

Abbott Media:

Darcy Ross, 224-667-3655

Kate Dyer, 224-668-9965

¹ First-quarter 2021 diluted EPS from continuing operations on a GAAP basis reflects 233.3 percent growth.

² Full-year 2021 guidance for diluted EPS from continuing operations on a GAAP basis reflects growth of at least 50 percent versus the prior year.

³ Excluding COVID-19 testing-related sales, Core Laboratory Diagnostics sales increased 14.1 percent and Molecular Diagnostics sales increased 33.9 percent on a reported basis in the first quarter.

6

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

First Quarter Ended March 31, 2021 and 2020

(in millions, except per share data)

(unaudited)

			1Q21				1Q20				% Change
Net Sales		$	10,456			$	7,726				35.3

Cost of products sold, excluding amortization expense			4,401				3,281				34.1
Amortization of intangible assets			509				561				(9.2	)
Research and development			654				578				13.3
Selling, general, and administrative			2,783				2,548				9.2
Total Operating Cost and Expenses			8,347				6,968				19.8

Operating Earnings			2,109				758				178.0

Interest expense, net			124				121				2.2
Net foreign exchange (gain) loss			3				5				(44.7	)
Other (income) expense, net			(61	)			(1	)			n/m
Earnings from Continuing Operations before taxes			2,043				633				222.7

Tax expense on Earnings from Continuing Operations			250				89				180.6		1	)
Earnings from Continuing Operations			1,793				544				229.5

Earnings from Discontinued Operations, net of taxes			--				20				n/m

Net Earnings		$	1,793			$	564				217.8

Earnings from Continuing Operations, excluding
Specified Items, as described below		$	2,368			$	1,162				103.8		2	)

Diluted Earnings per Common Share from:
Continuing Operations		$	1.00			$	0.30				233.3
Discontinued Operations			--				0.01				n/m
Total		$	1.00			$	0.31				222.6

Diluted Earnings per Common Share from Continuing
Operations, excluding Specified Items, as described below		$	1.32			$	0.65				103.1		2	)

Average Number of Common Shares Outstanding
Plus Dilutive Common Stock Options			1,792				1,781

NOTES:

See tables on page 9 for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following page.

7

1)	2021 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $80 million in excess tax benefits associated with share-based compensation.

2)

2021 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $575 million, or $0.32 per share, for intangible amortization and other net expenses primarily associated with certain litigation, acquisitions and restructuring actions.

2020 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $618 million, or $0.35 per share, for intangible amortization expense and other expenses primarily associated with acquisitions and restructuring actions.

8

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information From Continuing Operations

First Quarter Ended March 31, 2021 and 2020

(in millions, except per share data)

(unaudited)

		1Q21
		As Reported (GAAP)				Specified Items				As Adjusted				% to Sales

Intangible Amortization		$	509			$	(509	)		$	--
Gross Margin			5,546				549				6,095				58.3	%
R&D			654				(28	)			626				6.0	%
SG&A			2,783				(154	)			2,629				25.1	%
Other (income) expense, net			(61	)			(12	)			(73	)
Earnings from Continuing Operations before taxes			2,043				743				2,786
Tax expense on Earnings from Continuing Operations			250				168				418
Earnings from Continuing Operations			1,793				575				2,368
Diluted Earnings per Share from Continuing Operations		$	1.00			$	0.32			$	1.32

Specified items reflect intangible amortization expense of $509 million and other net expenses of $234 million, primarily associated with certain litigation, acquisitions, restructuring actions and other expenses. See page 11 for additional details regarding specified items.

		1Q20
		As Reported (GAAP)				Specified Items				As Adjusted				% to Sales

Intangible Amortization		$	561			$	(561	)		$	--
Gross Margin			3,884				599				4,483				58.0	%
R&D			578				(15	)			563				7.3	%
SG&A			2,548				(58	)			2,490				32.2	%
Other (income) expense, net			(1	)			(42	)			(43	)
Earnings from Continuing Operations before taxes			633				714				1,347
Tax expense on Earnings from Continuing Operations			89				96				185
Earnings from Continuing Operations			544				618				1,162
Diluted Earnings per Share from Continuing Operations		$	0.30			$	0.35			$	0.65

Specified items reflect intangible amortization expense of $561 million and other expenses of $153 million, primarily associated with acquisitions, restructuring actions and other expenses. See page 12 for additional details regarding specified items.

9

A reconciliation of the first-quarter tax rates for continuing operations for 2021 and 2020 is shown below:

		1Q21
($ in millions)			Pre-Tax Income				Taxes on Earnings				Tax Rate
As reported (GAAP)		$	2,043			$	250				12.2	%	1	)
Specified items			743				168
Excluding specified items		$	2,786			$	418				15.0	%

		1Q20
($ in millions)			Pre-Tax Income				Taxes on Earnings				Tax Rate
As reported (GAAP)		$	633			$	89				14.0	%
Specified items			714				96
Excluding specified items		$	1,347			$	185				13.7	%

1)

2021 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $80 million in excess tax benefits associated with share-based compensation.

10

Abbott Laboratories and Subsidiaries

Details of Specified Items

First Quarter Ended March 31, 2021

(in millions, except per share data)

(unaudited)

		Acquisition or Divestiture- related (a)				Restructuring and Cost Reduction Initiatives (b)				Intangible Amortization				Other (c)				Total Specifieds
Gross Margin		$	19			$	19			$	509				2			$	549
R&D			(2	)			--				--				(26	)			(28	)
SG&A			(13	)			(1	)			--				(140	)			(154	)
Other (income) expense, net			--				1				--				(13	)			(12	)
Earnings from Continuing Operations before taxes		$	34			$	19			$	509			$	181				743
Tax expense on Earnings from Continuing Operations (d)																			168
Earnings from Continuing Operations																		$	575
Diluted Earnings per Share from Continuing Operations																		$	0.32

The table above provides additional details regarding the specified items described on page 9.

a)

Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites.

c)

Other primarily relates to the net costs related to certain litigation, the acquisition of a research and development asset, and the impairment of an equity investment.

d)

Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.

11

Abbott Laboratories and Subsidiaries

Details of Specified Items

First Quarter Ended March 31, 2020

(in millions, except per share data)

(unaudited)

		Acquisition or Divestiture- related (a)				Restructuring and Cost Reduction Initiatives (b)				Intangible Amortization				Other (c)				Total Specifieds
Gross Margin		$	23			$	15			$	561			$	--			$	599
R&D			(4	)			(6	)			--				(5	)			(15	)
SG&A			(28	)			(30	)			--				--				(58	)
Other (income) expense, net			2				--				--				(44	)			(42	)
Earnings from Continuing Operations before taxes		$	53			$	51			$	561			$	49				714
Tax expense on Earnings from Continuing Operations (d)																			96
Earnings from Continuing Operations																		$	618
Diluted Earnings per Share from Continuing Operations																		$	0.35

The table above provides additional details regarding the specified items described on page 9.

a)

Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired business and include expenditures for retention, severance, and the integration of systems, processes and business activities.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites.

c)

Other primarily relates to the impairment of an investment.

d)

Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.

###

12

EX-101.SCH 3 abt-20210420.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 abt-20210420_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 abt-20210420_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Stock [Member] Entity Listings, Exchange [Axis] CHICAGO STOCK EXCHANGE, INC [Member] NEW YORK STOCK EXCHANGE, INC. [Member] Entity Listings [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 abt-20210420_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm2024852d1ex99-1img_001.jpg GRAPHIC begin 644 tm2024852d1ex99-1img_001.jpg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end XML 8 tm2113390d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000001800 2021-04-20 2021-04-20 0000001800 us-gaap:CommonStockMember exch:XCHI 2021-04-20 2021-04-20 0000001800 us-gaap:CommonStockMember exch:XNYS 2021-04-20 2021-04-20 iso4217:USD shares iso4217:USD shares 0000001800 false Common Shares, Without Par Value ABT 8-K 2021-04-20 ABBOTT LABORATORIES IL 1-2189 36-0698440 100 Abbott Park Road Abbott Park IL 60064-6400 224 667-6100 false false false false Common Shares, Without Par Value ABT NYSE CHX false XML 9 R1.htm IDEA: XBRL DOCUMENT

Cover	Apr. 20, 2021
Document Information [Line Items]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Apr. 20, 2021
Entity File Number	1-2189
Entity Registrant Name	ABBOTT LABORATORIES
Entity Central Index Key	0000001800
Entity Tax Identification Number	36-0698440
Entity Incorporation, State or Country Code	IL
Entity Address, Address Line One	100 Abbott Park Road
Entity Address, City or Town	Abbott Park
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60064-6400
City Area Code	224
Local Phone Number	667-6100
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Common Stock [Member] \| CHICAGO STOCK EXCHANGE, INC [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Shares, Without Par Value
Trading Symbol	ABT
Security Exchange Name	CHX
Common Stock [Member] \| NEW YORK STOCK EXCHANGE, INC. [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Shares, Without Par Value
Trading Symbol	ABT
Security Exchange Name	NYSE

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 3 96 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://abbott.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2113390d1_8k.htm abt-20210420.xsd abt-20210420_def.xml abt-20210420_lab.xml abt-20210420_pre.xml tm2113390d1_ex99-1.htm http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/exch/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2113390d1_8k.htm": { "axisCustom": 0, "axisStandard": 2, "contextCount": 3, "dts": { "definitionLink": { "local": [ "abt-20210420_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2113390d1_8k.htm" ] }, "labelLink": { "local": [ "abt-20210420_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "abt-20210420_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "abt-20210420.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 68, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 3, "nsprefix": "abt", "nsuri": "http://abbott.com/20210420", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2113390d1_8k.htm", "contextRef": "From2021-04-20to2021-04-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://abbott.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2113390d1_8k.htm", "contextRef": "From2021-04-20to2021-04-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings, Exchange [Axis]" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "exch_XCHI": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHICAGO STOCK EXCHANGE, INC [Member]" } } }, "localname": "XCHI", "nsuri": "http://xbrl.sec.gov/exch/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "exch_XNYS": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW YORK STOCK EXCHANGE, INC. [Member]" } } }, "localname": "XNYS", "nsuri": "http://xbrl.sec.gov/exch/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 17 0001104659-21-052205-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-052205-xbrl.zip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�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end